Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD99 is a therapeutic target on disease stem cells in myeloid malignancies.

Science translational medicine - 25 Jan 2017

Chung Stephen S, Eng William S, Hu Wenhuo, Khalaj Mona, Garrett-Bakelman Francine E, Tavakkoli Montreh, Levine Ross L, Carroll Martin, Klimek Virginia M, Melnick Ari M, Park Christopher Y

Abstract excerpt

Acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS) are initiated and sustained by self-renewing malignant stem cells; thus, eradication of AML and MDS stem cells is required for cure. We identified CD99 as a cell surface protein frequently overexpressed on AML and MDS stem cells. Expression of CD99 allows for prospective separation of leukemic stem cells (LSCs) from functionally normal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Cell Membrane

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Separation

Share to Hematopoietic Stem Cells

Share to Leukemia, Myeloid, Acute

Share to Myelodysplastic Syndromes

Share to Neoplasm Transplantation

Share to Research Design

Source

Open in PubMed Open full text

Identifiers

PMID: 28123069
DOI: 10.1126/scitranslmed.aaj2025
PMCID: PMC5624309

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD99 is a therapeutic target on disease stem cells in myeloid malignancies.PMID 28123069Read ↗

Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemiaSemantic proximity Read ↗

CD99 is a potential diagnostic and immunological biomarker in pan-cancerSemantic proximity Read ↗

CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemiaSemantic proximity Read ↗

Human leukaemic stem cells: a novel target of therapy.Semantic proximity Read ↗

Death induction by CD99 ligation in TEL/AML1-positive acute lymphoblastic leukemia and normal B cell precursorsSemantic proximity Read ↗

CD200 expression marks leukemia stem cells in human AMLSemantic proximity Read ↗

c-MPL Is a Candidate Surface Marker and Confers Self-Renewal, Quiescence, Chemotherapy Resistance, and Leukemia Initiation Potential in Leukemia Stem CellsSemantic proximity Read ↗

A STAT5B–CD9 axis determines self-renewal in hematopoietic and leukemic stem cellsSemantic proximity Read ↗

CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid LeukemiaSemantic proximity Read ↗

CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesisSemantic proximity Read ↗

Detection of molecular targets on the surface of CD34+/CD38− stem cells in various myeloid malignanciesSemantic proximity Read ↗

CD59 organizes the plasma membrane to sustain oncogenic Ras-MAPK signaling and is a targetable vulnerability in acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.